refresh your memory from gsk website

Relenza (zanamivir) anti-viral treatment production
GSK has been working with governments to supply Relenza, for use in a pandemic situation, since the global spread of H5N1 which began in 2003. Relenza has typically been used to diversify and add to government stockpiles of oseltamivir (Tamiflu).

Clinical tests have confirmed that pandemic (H1N1) 2009 is sensitive to inhibitors of neuraminidase such as Tamiflu and Relenza. Following the outbreak, GSK has contacted governments around the world to ascertain demand for Relenza and has put in place a series of measures to raise production levels. As a result, GSK now expects to increase its annual production capacity of Relenza to 190 million treatment courses by the end of 2009. This represents a threefold increase to GSKs previous maximum capacity of 60 million treatment courses.

This new capacity has been achieved by increasing production levels of Relenza Diskhaler from 60 million treatment courses to 90 million and building new capacity to produce 100 million treatment courses a year of Relenza Rotacaps. This alternative Relenza treatment was granted temporary approval by Swedish regulators earlier this month, as part of an application submitted under the European mutual recognition procedure for distribution during a pandemic. GSK is in discussions with regulatory authorities around the world to secure further approvals.

GSK has CONTRACTS IN PLACE to supply Relenza to OVER 60 GOVERNMENTS. GSK has also allocated 10% of its new Relenza production capacity for developing countries. Included within this capacity is an intended donation of 2 million doses of Relenza to the WHO. GSK is also operating a tiered-pricing policy for Relenza, again based on World Bank classification of countries. In line with GSKs commitments set out in March to make our branded medicines more affordable to the world's poorest people, Relenza will continue to be sold at not-for-profit prices to least developed countries.

GSK remains committed to engaging in voluntary license discussions with other companies willing to manufacture and supply a Relenza product for use in developing countries